News
Cipla launches the world’s first generic Pirfenidone in India
Cipla, among the world's leading generic pharmaceutical companies has introduced Pirfenidone in India; under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5...
News
Sandoz announces launch of piperacillin and tazobactam for injection, a generic version of Zosyn
Sandoz anounced the launch of piperacillin and tazobactam for injection, a generic equivalent of Zosyn®, in the US. Piperacillin and tazobactam for injection is an antibacterial treatment indicated for use in adults with certain types of moderate to severe...
News
Bharat Biotech Announces Launched Indias First Cell-culture H1N1 Swine Flu Vaccine
Bharat Biotech announced the launch of India?s first indigenously developed cell culture H1N1 swine fluvaccine under the brand name „HNVAC™. HNVAC™ is the only developing world flu vaccine to be manufactured in cell culture, a highly sterile and controlled...
News
Sanofi-aventis Establishes Research Collaboration with Harvard University
Sanofi-aventis announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientificex change between Harvard University and sanofi-aventis. The...
News
FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules
Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release Capsules, in the US market. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA...
News
First HIV diagnostic assay Results Available in Less Than 50 Minutes
Ortho Clinical Diagnostics announced U.S. FDA approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems. This is...
News
Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
Cephalon, Inc.announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
